The present study extends the recognized role of TRIM56 in antiviral innate immunity (15) and offers a potential pharmaceutical intervention strategy for NAFLD by targeting the TRIM56/FASN axis. Here, FASN is linked to metabolic dysfunction-associated steatotic liver disease.